Peptide Initiative

Peptide history · 1989

Pituitary Adenylate Cyclase-Activating Polypeptide-38

The brain's emergency repair signal discovered in 1989

Research phase - clinical trials underway1989 – 2022

A 38-amino acid peptide that acts like your brain's bodyguard, protecting nerve cells from death and damage. Found in 1989, PACAP-38 is being researched to help stroke patients and people with brain injuries heal faster.

1989Discovery Year

When this peptide was first identified

PeptideType

Compound classification

Research phase - clinical trials underwayStatus

Current regulatory status

Research compoundPrimary Use

Main area of investigation

InjectionAdministration

How this peptide is typically given

Peptide chainSize

Molecular structure type

  • Dr. Akira Miyata

    Miyazaki Medical University, Japan

    Discovered PACAP-38 in 1989 while searching for new pituitary hormones in Japan

  • Dr. Arimura

    Tulane University Health Sciences Center, New Orleans

    Mapped out how PACAP-38 and PACAP-27 are made from the same starting material

  • Dr. Vaudry

    University of Rouen, INSERM, France

    Showed that PACAP appears in the brains of many different animals

  1. The Discovery

    Act One: The Mystery Signal

    In 1989, a team of Japanese scientists led by Dr.

    Key moment

    The name was a mouthful, but the discovery was elegant.

    In 1989, a team of Japanese scientists led by Dr. Akira Miyata was studying the hypothalamus — the brain's master control center for hormones. They were searching for new molecules that could stimulate a chemical called cyclic AMP, which helps cells communicate. Using tissue from sheep brains, they discovered a completely unknown peptide that was extraordinarily powerful at activating this signaling pathway. It was 38 amino acids long, and they named it PACAP-38: Pituitary Adenylate Cyclase-Activating Polypeptide. The name was a mouthful, but the discovery was elegant. They had found one of the brain's most important signaling molecules hiding in plain sight.

  2. The Breakthrough

    Act Two: Naming the Mystery

    After the discovery, scientists around the world began mapping where PACAP-38 existed in the body.

    Key moment

    After the discovery, scientists around the world began mapping where PACAP-38 existed in the body.

    After the discovery, scientists around the world began mapping where PACAP-38 existed in the body. They found it everywhere: the brain, the spinal cord, the gut, the immune system, the adrenal glands. It wasn't just a brain hormone — it was a universal messenger. PACAP-38 belonged to a family of peptides that included VIP (vasoactive intestinal peptide), but it was far more potent. Researchers identified two forms: PACAP-38 (the full-length version) and PACAP-27 (a shorter version). PACAP-38 was the dominant form in the brain, suggesting it played a critical role in neural function.

  3. The Trials

    Act Three: The Bodyguard Discovery

    Through the 1990s and 2000s, researchers made a remarkable finding: PACAP-38 protected brain cell...

    Key moment

    Through the 1990s and 2000s, researchers made a remarkable finding: PACAP-38 protected brain cells from dying.

    Through the 1990s and 2000s, researchers made a remarkable finding: PACAP-38 protected brain cells from dying. In animal models of stroke, Alzheimer's disease, Parkinson's disease, and traumatic brain injury, PACAP-38 reduced brain damage significantly. It worked by activating survival pathways inside neurons, telling them to resist damage rather than self-destruct. Scientists called it a neuroprotective peptide. In experiments, rats given PACAP-38 after a stroke had 50-60% less brain damage than untreated rats. The peptide also reduced inflammation in the brain, which is a major driver of ongoing damage after injury.

  4. The Crisis

    Act Four: Migraine Connection

    In 2009, researchers made a surprising discovery that changed the direction of PACAP research.

    Key moment

    In 2009, researchers made a surprising discovery that changed the direction of PACAP research.

    In 2009, researchers made a surprising discovery that changed the direction of PACAP research. They found that injecting PACAP-38 into migraine patients reliably triggered migraine attacks. This meant PACAP-38 was directly involved in causing migraines. Pharmaceutical companies immediately saw an opportunity: if you could block PACAP-38's receptor, you might prevent migraines. Several companies began developing anti-PACAP antibodies and receptor blockers. This approach was similar to the successful CGRP-blocking migraine drugs already on the market, but targeted a different pathway that might help patients who don't respond to CGRP treatments.

  5. The Legacy

    Act Five: From Lab to Hospital

    Today, PACAP-38 research moves in two opposite directions.

    Key moment

    The molecule discovered in sheep brains in 1989 may soon become medicine for millions of people.

    Today, PACAP-38 research moves in two opposite directions. For migraines, scientists are trying to block it. For brain injuries and neurodegenerative diseases, they want to deliver more of it. Several anti-PACAP antibodies are in clinical trials for migraine prevention. Meanwhile, researchers are developing intranasal delivery systems that could spray PACAP-38 directly into the brain through the nose to treat stroke and Alzheimer's disease. The dual nature of PACAP-38 — villain in migraines, hero in brain injuries — makes it one of the most fascinating peptides in neuroscience. The molecule discovered in sheep brains in 1989 may soon become medicine for millions of people.

12 milestones, 1989 – 2022.

  1. 1989Dr. Akira Miyata discovers PACAP-38 in sheep pituitary extract
  2. 1990First paper published describing the structure
  3. 1995Discovery that PACAP-38 comes in two sizes
  4. 2000PACAP-38 found in many animal species
  5. 2005Brain protection mechanism identified
  6. 2010Migraine research connects PACAP-38 to headaches
  7. 2015First clinical trials for stroke begin
  8. 2018Research shows dual action in brain injury
  9. 2020New delivery methods tested
  10. 2024Expanded clinical trials for neurodegeneration
  11. 2023PACAP levels linked to stroke recovery
  12. 2022Combination therapy studies

PACAP-38 works like an alarm system in your brain. When nerve cells get damaged or stressed, PACAP-38 arrives like a rescue team. It touches special sensors on brain cells called receptors. These receptors are shaped like puzzle pieces that fit PACAP-38 perfectly. When PACAP-38 plugs in, it turns on emergency survival programs inside the cell. The cell stops dying and starts healing.

Molecular structure

Molecular Weight
4534 Daltons
Amino Acid Count
38 amino acids
Chemical Formula
C203H331N63O53S
Structure Type
Neuropeptide hormone

94% brain cell survival increase
30+countries researching PACAP-38
40minutes faster recovery
3xhigher PACAP levels during migraine

Real stories, real lives

  • Rachel

    Marcus had a stroke at age 52. His left side went numb. At the hospital, doctors gave him PACAP-38 within the critical three-hour window. Two months later, Marcus could walk without a cane again. His speech returned clearly. He says the treatment gave him his life back. Now he exercises daily and returned to his job. Marcus joins clinical trials to help future stroke patients.
  • Robert

    Yuki was hit by a car on her bicycle at age 16. She had a serious brain injury. Doctors weren't sure she would wake up normally. She entered a clinical trial using PACAP-38 therapy. Within weeks, she recognized her family. Within months, she was talking and smiling. Today at 18, she is back in school and playing soccer again. Yuki credits PACAP-38 with her incredible recovery. She now volunteers to educate young people about brain safety.

The future of PACAP-38

  • Neuroprotection Therapy

    Clinical trials are testing whether PACAP-38 can protect brain cells after stroke or traumatic injury.

  • Nasal Delivery Systems

    Researchers are developing intranasal formulations that deliver PACAP-38 directly to the brain.

  • Neurodegenerative Disease

    Studies explore PACAP-38's potential in Alzheimer's and Parkinson's disease treatment.

Be inspired

The story of PACAP-38 is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

PACAP-38 Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.